Recent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...

Evofem at Critical Stretch with Potential New Birth Control

BIOTECH: Contraceptive Gel Is Part of CEO's Health Mission for WomenEvofem Biosciences wants to be the next big thing in birth control. After a long road, the San Diego biotech finds itself in a pivotal stretch.

Metacrine Secures $50M Loan and Security Deal

San Diego-based Metacrine has inked a loan and security agreement for up to $50 million with K2 HealthVentures.

Pursuing ‘Untapped Biology,’ Boundless Bio Lands $46.4M Funding Round

Boundless Bio Inc. emerged Sept. 19 with $46.4 million in funding and a claim to new territory: extrachromosomal DNA

Acadia Pharmaceuticals Plans $250M Stock Offering

Acadia Pharmaceuticals is planning to raise $250 million through a public stock offering.

$161B Market Seen in ‘Functional Foods’

HEALTH: Consumer Focus on Nutrition Drives Demand

More and more, San Diego-based food companies are placing focus on including functional ingredients in their “better for you” offerings.

Tease photo

DelMar Pharmaceuticals Relocates to San Diego

DelMar Pharmaceuticals has relocated from British Columbia to San Diego.

SGI-DNA Pulls in $25M Series A Round for DNA Printer

San Diego’s SGI-DNA, a spinout of Synthetic Genomics, has raised a $25 million series A round.

Company Has Instrument of Change for Dermatology

MEDICINE: DermTech’s Patch May Change Skin Cancer Diagnostics

Could that suspicious mole be cancerous? DermTech wants doctors to reach for a patch, not a scalpel.

Tease photo

SDBJ INSIDER: The Wait May Soon Be Over

Obalon Therapeutics Inc. announced Dr. Helmuth Billy as medical director for its first company-owned weight-loss treatment center.

Turning Point Therapeutics Raises $202.5M in Follow-On Offering

BIOTECH: Cancer Drug Developer Plans To Build Its Pipeline

After raising $175.2 million in an initial public offering this spring, Turning Point Therapeutics has returned to the public market.

Tease photo

Tocagen’s Brain Cancer Therapy Fails Clinical Trial

Shares of Tocagen fell Sept. 12 after its brain cancer therapy failed a late-stage clinical trial.

Turning Point Therapeutics Raises $202.5M in Follow-On Offering

The cancer drug developer on Sept. 10 raised $202.5 million in a follow-on offering. Turning Point sold 4.5 million shares of common stock at a price of $45 a share.

Capping Off An Unusual Pact, GlaxoSmithKline Buys Sitari Pharmaceuticals

GlaxoSmithKline announced it will acquire San Diego’s Sitari Pharmaceuticals – a deal induced by an unusual pact.

Health Systems Try Ride-Sharing Solutions

MEDICINE: Getting Patients to Appointments or Home Is Goal

An increasingly common destination for Lyft and Uber drivers: San Diego hospitals.

Center Is S.D.’s ‘First Academic-Industry Drug Discovery Incubator’

UC San Diego Offering Space to Pharma Industry To Help Develop Drugs

UC San Diego Moores Cancer Center is offering up space on its campus to the pharmaceutical industry in a bid to translate research into medicines for cancer patients.

Tease photo

Cidara’s Deal for Antifungal Drug Could Be Worth $568M+

Mundipharma’s Backing Will Extend Runway, Provide Well-Positioned Support

Clinical trial results have yielded a major payout for Cidara Therapeutics, a San Diego company developing an antifungal drug.